Epidemiology
It affects tendon sheaths or joints; the localized form is common in the hand, and the diffuse form in the knee or other joints. In joints it can present as recurrent effusions, locking, or stiffness, not only as a palpable mass.
Basic features
It causes swelling, stiffness, pain, or repeated joint effusions. The diffuse form was previously known as pigmented villonodular synovitis (PVNS).
Usual treatment
Removal of the tumor or of the joint lining (synovectomy). For the symptomatic diffuse form, when surgery is not possible or would mean a major loss of function, targeted systemic therapies against CSF1R (pexidartinib or vimseltinib) may be considered. These are specialist drugs and not a first-line option: pexidartinib requires strict monitoring of liver function because of the risk of serious liver injury, and the availability of both varies from country to country.
Outcomes and prognosis
The localized form is usually well controlled, with a low recurrence rate; the diffuse form recurs more often and requires long-term follow-up. Malignant transformation is exceptional.
